New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...

The share price of Shilpa Medicare (NSE: SHILPAMED) closed at Rs 909.90 on August 14, 2025, representing a slight increase of ...

Zydus Lifesciences Limited has announced its unaudited consolidated financial results for the first quarter ended June 30, ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie, in collaboration with REGENXBIO Inc., is ...

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...

D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

Second-Quarter 2025 and Recent Selected Highlights: <li /> Total revenues of $63.7 million, a 30% increase over $48.

Recently, VivaVision Biotech (Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board.